Cancer Treatments Gene Therapy Neurology Alzheimer's Disease Hospitalization Transgender Health Surgical Procedures Pharmaceuticals Oxygen Therapy In Vitro Fertilization Migraine Treatments Pharmacology Antibiotics Allergic Reactions FDA Approvals Hyperbaric Oxygen Therapy Hormone Replacement Therapy Pain Management Obstructive Sleep Apnea Sleep Disorders Antibiotic Therapy Dialysis Cancer Treatment Stem Cell Therapy Anaphylaxis Treatment Blood Pressure Management Stem Cell Transplantation Drug Approvals Trauma Care Hormonal Therapies Oncology Biosimilars HIV Migraine Management Migraine Cannabis Treatment Weight Loss Multiple Sclerosis Transgender Youth Therapies Organ Transplantation Cellular Therapies Therapeutics Plasma-derived Medicines Controversial Practices Adolescent Care Genetic Disorders Asthma Treatments Respiratory Conditions Gender-Transition Treatments Cryotherapy Cell Therapy Antivenom Hyperbaric Therapy Antibiotic Treatments Surgery Interventional Procedures Corticosteroids Cardiology Blood Transfusion Noninvasive Ventilation Hospital Care Allergies Immunotherapy Asthma Ophthalmology Cost of Healthcare Hormonal Treatments Clinical Trials Diabetes Medications Cannabis Endometriosis Transfusions Osteoporosis Hemophilia Probiotics
Phase II trial results presented at AACR 2025 confirm significant improvements in rash severity and quality of life without compromising cancer treatment efficacy.